Kirkegaard: J&J Suspension is Bad News for Europe
Johnson & Johnson’s decision to temporarily suspend distribution to the European Union while it conducts a review on blood clots adds pressure on vaccination targets for the bloc. That’s according to Jacob Kirkegaard, senior fellow at the German Marshall Fund. Any delays could have ramifications for travel and leisure sectors ahead of the summer reopening. He speaks in an episode of The Brussels Edition with Bloomberg’s Maria Tadeo.